Request Demo

Last update 01 Aug 2026

Durvalumab

Last update 01 Aug 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Durvalumab (Genetical Recombination), Durvalumab (genetical recombination) (JAN), Durvalumab (USAN/INN)

+ [10]

Target

PDL1

Action

inhibitors

Mechanism

PDL1 inhibitors(Programmed death-ligand 1 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [11]

Active Indication

Non-Muscle Invasive Bladder NeoplasmsStomach CancerEarly gastric cancer+ [180]

Inactive Indication

Acute Myeloid LeukemiaAdenocarcinoma of LungAdenocarcinoma of prostate+ [93]

Originator Organization

AstraZeneca UK Ltd.

Active Organization

AstraZeneca PLC

AstraZeneca Investment (China) Co. Ltd.AstraZeneca AB

+ [17]

Inactive Organization

Fred Hutchinson Cancer Research Center

Plexxikon, Inc.

MedPacto, Inc.

+ [7]

License Organization

MedImmune Pharma BV

Ultimovacs ASAVall d'Hebron Institut d'Oncologia

+ [14]

Drug Highest PhaseApproved

First Approval Date

United States (01 May 2017),

Transitional Cell Carcinoma

RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Priority Review (United States)

Structure/Sequence

Sequence Code 10069506H

Source: *****

Sequence Code 13384675L

Source: *****

926

Clinical Trials associated with Durvalumab

NCT07639528

/ Not yet recruitingPhase 2IIT

Phase II, Open Label, Non-Randomized, Study of Optimal Preoperative Therapy for Intrahepatic Cholangiocarcinoma (OPTIC)

This phase II trial tests the safety and effectiveness of preoperative immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine with or without futibatinib targeted therapy in treating patients with intrahepatic cholangiocarcinoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine and/or targeted therapy with futibatinib before surgery may make the tumor smaller for resection and may help prevent the cancer from coming back. Patients whose molecular profiling test result show a genetic change called FGFR2 fusion, rearrangement, or activating mutation, receive immunotherapy, chemotherapy and targeted therapy while patients without a FGFR2 fusion, rearrangement, or activating mutation just receive immunotherapy and chemotherapy. Giving targeted therapy based on molecular profile test results prior to attempted resection for patients with intrahepatic cholangiocarcinoma that has a risk for either not being able to be removed or for coming back after it has been removed may help improve treatment outcomes in patients with resectable intrahepatic cholangiocarcinoma.

Start Date10 Dec 2027

Sponsor / Collaborator

Northwestern University

[+1]

NCT07637513

/ Not yet recruitingPhase 3

Phase III Trial of Consolidation Tarlatamab + Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer (LS-SCLC)

Eligible participants with limited stage-small cell lung cancer (LS-SCLC) will be enrolled after completion of chemotherapy and radiation. Participants will be randomized to either tarlatamab in combination with durvalumab or durvalumab alone as consolidation therapy. Treatment will continue until disease progression, unacceptable side effects or withdrawal of consent.
Tarlatamab is a targeted cancer treatment. It works by acting as a matchmaker between the immune system's T-cells and the cancer cells, forcing them to come together so the T-cells can attack the cancer.
Image testing will be done standardly during treatment. These tests show whether the cancer has progressed and if further treatment may be needed.
The purpose of this trial is to evaluate how well the treatment works (how long before your cancer comes back and how long you live).

Start Date01 Jan 2027

Sponsor / Collaborator

Amgen, Inc.

NCT07625930

/ Not yet recruitingPhase 2IIT

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial: A Phase II Randomized Open-Label Trial of Perioperative Simvastatin Plus Standard-of-Care Systemic Therapy in Gastroesophageal Adenocarcinoma

Esophageal and gastroesophageal junction cancers are serious diseases with limited cure rates, even when patients receive chemotherapy and surgery. New ways to improve treatment are urgently needed.
This study will test whether adding a commonly used cholesterol-lowering medication, simvastatin, to standard cancer treatment can improve outcomes. Simvastatin is widely used, safe, and inexpensive. Research suggests that it may also slow cancer growth by blocking pathways that cancer cells rely on for survival.
In this trial, patients will receive standard chemotherapy (with or without immunotherapy) before surgery. Half of the patients will also take simvastatin daily for up to two years. Researchers will compare how well tumors respond to treatment and whether patients remain cancer-free longer.
If successful, this approach could offer a simple and accessible way to improve survival for patients with these cancers without adding significant side effects or cost.

Start Date01 Jan 2027

Sponsor / Collaborator-

100 Clinical Results associated with Durvalumab

100 Translational Medicine associated with Durvalumab

100 Patents (Medical) associated with Durvalumab

2,534

Literatures (Medical) associated with Durvalumab

01 Oct 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Systematic development and optimization of a cIEF method for the charge variants analysis of moderately basic to basic monoclonal antibodies using the Analytical Quality by Design strategy

Article

Author: Orlandini, Serena ; Massolini, Gabriella ; Furlanetto, Sandra ; Pasquini, Benedetta ; Floris, Lucrezia ; Luciani, Francesca ; Gotti, Roberto

This study proposes a Capillary IsoElectric Focusing Analytical Procedure Platform for the charge heterogeneity characterization of monoclonal antibodies. The Analytical Quality by Design approach was implemented to define a robust Method Operable Design Region using Infliximab as the primary model compound. The Analytical Target Profile consisted in a robust Analytical Procedure Platform able to measure the monoclonal antibody isoforms pI values with a bias lower than 4%. Risk Management tools were used to evaluate and control the risk of Analytical Target Profile failure. Risk Analysis identified several potential Critical Procedure Parameters, including urea and methyl cellulose concentrations, cathodic/anodic stabilizer levels, carrier ampholytes composition. The carrier ampholytes composition was optimized utilizing a mixture design. A Scheffé mixture model allowed the selection of experiments, and the Partial Least Squares regression provided high predictive power models for the three defined responses, i.e. the calibration biases at the bracketing markers of Infliximab (pI 9.5 and pI 7.0) and the overall fit of the pI vs. migration time relationship. Within the Method Operable Design Region, the optimized conditions were achieved using as the specific carrier ampholyte a blend constituted of 1.5% at pH 3-10, 1.5% at pH 5-8, and 2.0% at pH 8-10.5. The validation results demonstrated the robustness of the Analytical Procedure Platform, with a bias in pI measurement lower than 0.3% for the markers bracketing the Infliximab isoforms. In addition, the method was validated for linearity, trueness and precision as degree of repeatability in the quantification of the charge variants of Infliximab. Under the same optimized experimental conditions, the method was applied to successfully profile Bevacizumab, Daratumumab, Trastuzumab and Durvalumab. By including molecules exhibiting a broader range of physicochemical properties compared to the Infliximab model, the study confirms the versatility of the proposed Capillary IsoElectric Focusing method for moderately basic to basic antibodies. This work provides a refined, regulatory-compliant conventional electrokinetic methodology for biopharmaceutical quality control.

01 Aug 2026·UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer

Article

Author: Masuda, Hitoshi ; Chen, Wei ; Hirakawa, Akihiro ; Fujii, Yasuhisa ; Yajima, Shugo ; Yoshida, Soichiro ; Fukushima, Hiroshi ; Sato, Hiroyuki ; Tanaka, Hajime

INTRODUCTION:

The NIAGARA trial demonstrated improved event-free survival (EFS) with perioperative durvalumab plus gemcitabine-cisplatin (GC) vs. GC alone in muscle-invasive bladder cancer (MIBC). This analysis applied mixture cure models to explore whether this EFS benefit may reflect an increase in the proportion of patients achieving long-term event-free status, complementing standard hazard ratio analyses.

METHODS:

Reconstructed individual patient data (rIPD) were derived from published Kaplan-Meier curves. Parametric mixture cure models (Weibull, log-logistic, and log-normal) were fitted separately by treatment arm, with model selection based on the Akaike Information Criterion (AIC). Cure regression models decomposed treatment effects into cure and latency components. Sensitivity analyses assessed robustness to reconstruction uncertainty and follow-up duration.

RESULTS:

The rIPD reproduced the published trial results with reasonable concordance (hazard ratio 0.68 vs. reported 0.68). The log-normal model provided the best fit. The estimated cure fraction (π) was 41% (95% confidence interval [CI]: 32%-48%) for the control arm and 60% (95% CI: 55%-65%) for the durvalumab arm, yielding a model-based difference (Δπ) of +19 percentage points (pp) (95% CI: +10 to +29). Akaike weights favored a cure-effect-only model (71%) over a combined cure-plus-latency model (29%), with a latency-only model receiving negligible support (<1%). Perturbation sensitivity analyses indicated that these bootstrap intervals underestimate total uncertainty, with individual-run estimates spanning negative values at plausible reconstruction noise levels.

CONCLUSIONS:

In this exploratory analysis of reconstructed individual patient data, perioperative durvalumab was associated with an estimated +19 pp higher cure fraction (95% CI: +10 to +29); cure regression assigned an Akaike weight of 71% to a pure cure fraction mechanism vs. 29% to a combined cure-plus-latency mechanism. These estimates depend on the reconstructed dataset and on the assumption that the EFS curves have plateaued within the observed follow-up; perturbation sensitivity analyses indicated that at plausible reconstruction noise (SD ≥ 0.5 months) the range of individual-run estimates spans negative values.

01 Aug 2026·LUNG CANCER

Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Article

Author: de Langen, Adrianus J ; Tang, Kwan Ho ; Piotrowska, Zofia ; Riess, Jonathan W ; Cetnar, Jeremy ; Garcia Campelo, M Rosario ; Smith, Paul E ; Le, Xiuning ; Novello, Silvia ; Ambrose, Helen ; Okamoto, Isamu ; Lehman, Jonathan M ; Cho, Byoung Chul ; Goldman, Jonathan W ; Shiraishi, Yoshimasa ; Yu, Helena A ; Kim, Yu Jung ; Goldberg, Sarah B

BACKGROUND:

ORCHARD (NCT03944772) was an open-label, phase 2 platform study that evaluated resistance mechanisms and post-progression treatments in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) with progressive disease (PD) on first-line osimertinib. We report final data from the module investigating durvalumab plus etoposide-platinum in patients with neuroendocrine transformation to small cell lung cancer or large cell neuroendocrine carcinoma.

METHODS:

Patients received durvalumab 1,500 mg intravenously every three weeks (Q3W) plus etoposide-platinum Q3W for up to four cycles. Durvalumab continued until PD, unacceptable toxicity or another discontinuation criterion was met. The primary endpoint was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary endpoints were progression-free survival (PFS), duration of response (DoR), overall survival (OS), and safety.

RESULTS:

Fourteen patients received treatment and were evaluable for efficacy/safety (data cutoff: January 21, 2025). Confirmed ORR was 43 % (80 % confidence interval [CI]: 24-63) (six partial responses). Median duration of response was 4.3 months (95 % CI: 3.0-not calculable); one patient had a response lasting 10 months. Progression-free survival (PFS) events were observed in 13 patients (93 %) and 11 patients (79 %) died. Median PFS was 4.2 months (95 % CI: 3.0-5.6) and median overall survival was 10.2 months (95 % CI: 4.3-16.8). Nine patients (64 %) reported grade ≥3 adverse events (AEs), most commonly neutropenia and decreased neutrophil count (four patients each), and one patient discontinued all three study drugs due to an AE (not treatment-related).

CONCLUSIONS:

Durvalumab plus etoposide-platinum demonstrated a modest treatment response in neuroendocrine-transformed EGFR-mutated NSCLC. AEs were concordant with the known safety profiles of the combination, and no new safety signals were observed.

TRIAL REGISTRATION:

ClinicalTrials.gov, NCT03944772.

1,287

News (Medical) associated with Durvalumab

30 Jul 2026

·www.biospace.com

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Completes Patient Enrollment in Phase II Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors

NANJING, China, July 30, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that the Phase II clinical study of its core product Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) for the treatment of first-line advanced biliary tract cancer (BTC) has completed enrollment of all 70 patients. In April 2026, the study successfully entered the expansion phase based on a favorable safety pro robust efficacy that exceeded expectations, and rapidly completed full patient enrollment, fully demonstrating the efficient clinical advancement and continuously validated significant efficacy of Opamtistomig. Despite the recent adoption of PD-(L)1 immunotherapy combined with chemotherapy as a first-line standard of care for advanced BTC, clinical benefits remain limited. Current standard regimens, including pembrolizumab plus chemotherapy and durvalumab plus chemotherapy, have demonstrated objective response rates (ORR) below 30% and median overall survival (OS) of only approximately 12–13 months, leaving a substantial unmet medical need in this aggressive malignancy. The potential of Opamtistomig as an IO 2.0 pan-tumor cornerstone therapy has been continuously validated across three dimensions: broad-spectrum anti-tumor activity, long-term survival benefit trends, and a safety pro to PD-(L)1 monoclonal antibodies. Existing data show that, following extrapulmonary neuroendocrine carcinoma (EP-NEC) and small cell lung cancer (SCLC), Opamtistomig has once again demonstrated highly competitive efficacy in BTC, a typical immune-cold tumor, with the potential to elevate the efficacy of immunotherapy in BTC to new heights. Given that the predominant pathological type of BTC is adenocarcinoma, combined with the positive data previously observed in squamous cell carcinoma subtypes of major cancer types such as non-small cell lung cancer (NSCLC), Opamtistomig has shown clear efficacy in both adenocarcinoma and squamous cell carcinoma types, with its broad-spectrum anti-cancer potential being continuously validated. The multicenter study is led by Academician Zhou Jian of Zhongshan Hospital, Fudan University and is being conducted across multiple hospitals in China. Results from safety run-in data showed that Opamtistomig in combination with chemotherapy demonstrated a favorable overall safety pro good tolerability, with no new safety signals identified. Preliminary efficacy assessments showed an encouraging tumor shrinkage. Detailed clinical data will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting to be held in Madrid, Spain from October 23 to 27, 2026. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Executive Commentary Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said: “The rapid progress of our Phase II BTC study reflects the strong confidence investigators and patients have placed in the encouraging efficacy signals generated by Opamtistomig to date. Immune-cold tumors remain among the greatest challenges in oncology and represent one of the most important frontiers for next generation immunotherapy. Across multiple immune-cold tumor types, Opamtistomig has consistently demonstrated promising clinical activity, further validating its potential as an IO 2.0 pan-tumor cornerstone therapy. We are committed to accelerating the clinical development of Opamtistomig in BTC and look forward to bringing a more effective and durable treatment option to patients with this devastating disease as early as possible.” About Biliary Tract Cancer Biliary tract malignancies primarily include gallbladder cancer and intrahepatic/extrahepatic cholangiocarcinoma, with approximately 419,100 new cases globally in 2024. These malignancies are predominantly ‌adenocarcinomas‌ with high invasiveness, and most cases are diagnosed at advanced stages, leading to ‌poor prognosis‌ (5-year survival rate <5%)‌. Currently, global incidence of biliary tract malignancies is rising, with the highest prevalence observed in Asian countries. Although ‌PD-1/L1 inhibitors combined with chemotherapy‌ have been approved as first-line treatment for advanced biliary tract malignancies, clinical benefits remain limited: ‌Modest improvement in median overall survival (OS)‌ (from ~11.5 to 12.8 months)‌ and ‌Low objective response rate (ORR)‌ (<30%)‌. These gaps highlight ‌unmet medical needs‌ for more effective therapies‌. About Opamtistomig Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs’ proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic anti-tumor immune response. It has a safety pro to PD-1/PD-L1 inhibitors and demonstrates broader-spectrum anti-cancer potential. To date, Opamtistomig has demonstrated first- or best-in-class potential in Phase II or registrational clinical trials across four indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), and extrapulmonary neuroendocrine carcinoma (EP-NEC). As the first 4-1BB–targeting bispecific antibody globally to advance to a single-arm pivotal trial as monotherapy, Opamtistomig has been evaluated in 13 solid tumor indications in China, including 1 pivotal registration trial and 8 proof-of-concept studies. These cover EP-NEC, NSCLC, SCLC, BTC, ovarian cancer (OC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), malignant melanoma, and other areas with high unmet medical needs. Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically “cold” tumors. Recognizing its clinical potential, Opamtistomig received Breakthrough Therapy Designation (BTD) from China’s National Medical Products Administration (NMPA) in October 2024, and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinoma in November 2024. Additionally, in January 2026, Opamtistomig was granted Fast Track Designation (FTD) by the FDA and ODD by the European Commission for the treatment of EP-NEC, further underscoring its potential to address unmet medical needs in this patient population. About Leads Biolabs Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally. Leads Biolabs is a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 14 innovative drug candidates, including four clinical-stage drug candidates and one registration-stage asset. The Company adopts a science-driven R&D approach and has successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. It has also developed multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone for its continued innovation and have been validated by the clinical outcomes of its bispecific antibody portfolios. Leads Biolabs has established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of its drug candidates, coupled with its global perspectives, proactive strategy, and efficient clinical validation, have made it an attractive partner for leading industry players and investment institutions. For more information, please visit CONTACT: Contact: yizi@leadsbiolabs.com

Phase 2Fast TrackImmunotherapyOrphan DrugClinical Result

29 Jul 2026

·www.fiercebiotech.com

Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination

After keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the evidence. A brief, now-deleted clinical trial listing on Merck’s website revealed that the New Jersey pharma plans to test the bispecific, coded MK-2010, alongside its TROP2-directed antibody-drug conjugate, sac-TMT. The phase 2 trial, coded MK-2010-003, was marked as “Study in start-up” on Merck’s website, with St. Gallen and Bellinzona in Switzerland listed as study centers. The open-label study would test the combo in patients with advanced solid tumors. Following a request for comment from Fierce Biotech on Wednesday morning, Merck has apparently removed the entry and deleted other listings for MK-2010, including a separate phase 2 monotherapy trial. The company didn’t reply to Fierce’s inquiry by publication time. China-based life sciences data aggregator PharmCube was among the first to report on the trial entry. The secrecy underscores a highly competitive race within the PD-(L)1xVEGF bispecific class, which also includes Summit Therapeutics and Akeso’s frontrunner ivonescimab , Bristol Myers Squibb and BioNTech’s pumitamig, and Pfizer and 3SBio’s PF-08634404 (SSGJ-707). Merck has kept its PD-1xVEGF strategy close to its chest since acquiring the asset from China’s LaNova Medicines (now part of Sino Biopharmaceutical) in 2024, citing a fiercely competitive environment . As bispecifics threaten to unseat Keytruda as the new immuno-oncology backbone, industry watchers and rivals alike have been closely tracking every move by the Keytruda maker while trying to decipher every comment the company makes. During an investor event on the sidelines of the 2026 American Society of Clinical Oncology annual meeting in June, Merck’s head of oncology global clinical development, Marjorie Green, M.D., pointed to the company’s experience combining Keytruda with VEGF inhibitors. She touted a “portfolio of novel agents that offer combination opportunities oriented towards combinations of the future rather than adding on to today’s current standard, including ADCs like sac-TMT.” Hints of Merck’s development plan for MK-2010 dropped as questions also began to swirl around potential competition—rather than synergy—between PD-1xVEGF drugs and TROP2 ADCs in the lucrative non-small cell lung cancer indication. As Akeso has reported ivonescimab head-to-head wins against PD-1 inhibitors in first-line NSCLC, Merck’s partner, Kelun-Biotech, has also delivered strong phase 3 results for sac-TMT in the same setting. Standing only on the verge of phase 2, Merck’s measured approach to MK-2010 reflects a cautious stance that contrasts sharply with the expansive phase 3 programs underway at BioNTech/BMS and Pfizer, as well as Merck’s own 17-trial roster for sac-TMT. For pumitamig , BioNTech and BMS have laid out the first wave of nine global pivotal trials across multiple tumor types, with lung cancer and breast cancer leading the way. In potential combinations of PD-1xVEGF and TROP2 ADC, specifically, Merck also appears to be behind. China’s Minghui Pharmaceutical is already about a year into phase 2 development , pairing its PD-1xVEGF candidate MHB039A with a TROP2 ADC coded MHB036C for advanced breast cancer and other solid tumors. Despite what appears to be a conservative approach so far, Leerink Partners analyst Daina Graybosch, Ph.D., has argued that Merck could rapidly pivot to more aggressive development of MK-2010 if it so chooses. “We believe Merck’s ‘wait-and-then-move’ strategy for MK-2010 will prove successful, as they have a strong portfolio to leapfrog the competition via ADC combinations,” Graybosch and colleagues wrote in an April note after Merck unveiled the first clinical data for MK-2010 in NSCLC at the American Association for Cancer Research annual meeting. “Should Merck proceed with MK-2010 more aggressively, we believe they are likely to leverage their vast ADC program (including […] sac-TMT) to combine with MK-2010,” the team said at the time. Meanwhile, the oncology field is eagerly waiting for phase 3 readouts from AstraZeneca and Daiichi Sankyo’s Avanzar trial for a cocktail of their TROP2 ADC, Datroway, with AZ’s PD-L1 inhibitor Imfinzi and chemotherapy in first-line NSCLC.

28 Jul 2026

·www.businesswire.com

Vizient Projects 3.54% Pharmacy Inflation and 4.73% Indirect Spend Inflation for 2027

IRVING, Texas--(BUSINESS WIRE)--Vizient released its summer 2026 Spend Management Outlook, projecting 3.54% pharmacy inflation and 4.73% indirect spend and purchased services inflation for 2027. Growth in technology, facilities, construction, and other non-clinical services reflects the expanding role these investments play in healthcare organizations' overall spending. Together, these trends are projected to drive overall supply chain, capital, and purchased services inflation to 3.39% in 2027, underscoring the need for healthcare organizations to manage costs across both clinical and operational categories. "The drivers of healthcare spending continue to evolve," said Carina Dolan, associate vice president, clinical oncology, pharmacoeconomics and market insights, Vizient. "As care expands beyond the hospital and organizations invest in technology and infrastructure, spending decisions are becoming increasingly interconnected. Understanding these trends is essential to making informed investment decisions while maintaining financial sustainability." Pharmacy spending continues to follow patients beyond the hospital Care will continue to move beyond the traditional hospital setting, reshaping where healthcare organizations invest and how they plan for future demand. Overall ambulatory pharmacy inflation is projected at 3.64%, driven by projected inflation of 4.04% for specialty and complex medications. GLP-1 therapies continue to reshape self-administered pharmacy spending. Tirzepatide rose to the No. 2 self-administered medication by spend, accounting for 3.47% of pharmacy spend, while semaglutide remained in the top five at 2.33%. Together, these two therapies now represent 5.80% of self-administered pharmacy spend, up from 4.74% in the winter 2026 Outlook. Annual utilization for tirzepatide increased 101.2% from 2024 to 2025 among Vizient Pharmacy Program participants, reflecting continued strong demand. Additionally, almost half of pharmaceutical spending will come from two categories that will also have two of the highest rates of price inflation: Oncology drugs, including Keytruda, Darzalex Faspro, Opdivo, and Imfinzi, account for 25.59% of pharmacy spending, with costs projected to increase 4.14%. Autoimmune and anti-inflammatory therapeutics, such as Skyrizi, Dupixent, Humira, and Enbrel, account for 23.39% of spending with costs projected to increase by 4.10%. Investment in technology infrastructure and operational services continues to fuel indirect spend growth As healthcare organizations continue investing in clinical informatics, AI-enabled diagnostics, and digital transformation, there will be growing costs associated with both the acquisition and utilization of these capabilities. Projections show the inflation increase of these indirect spend categories will be driven by continued increases in IT security (8.50%), IT hardware and accessories (8.00%), and IT software and licensing (7.50%) as organizations strengthen operations. Beyond technology spending, organizations continue to face growing pressure from wider macroeconomic trends driving up the cost of food (4.16% projected increase), construction (4.70%), and capital equipment (4.15%). These investments increasingly influence organizational resilience, services continuity and long-term performance, requiring greater coordination across finance, supply chain, operations, and clinical leadership. "Indirect spend has evolved from support categories into a strategic capability,” said Dolan. “Investments in technology and infrastructure increasingly influence how organizations deliver care, strengthen resiliency, and position themselves for future growth." Pharmacy projections for the summer 2026 Spend Management Outlook are based on Vizient client purchases April 2025–March 2026. Non-pharmacy supply chain projections are based on a Vizient analysis of various public sources including the U.S. Bureau of Labor Statistics, U.S. Department of Agriculture and Energy Information Administration. Read more in the Vizient Spend Management Outlook. About Vizient Vizient® enables healthcare providers to deliver better, more affordable care by improving financial sustainability, enhancing system performance, and accelerating strategic growth. More than two-thirds of the nation's acute care providers and more than one-third of ambulatory providers rely on Vizient solutions and services. By combining the nation’s most influential healthcare leader networks with industry-leading data and analytics, comprehensive solutions, and advisory services through Kaufman Hall, Vizient helps providers achieve financial, clinical, and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at vizient.com.

100 Deals associated with Durvalumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10808	Durvalumab	L01XC28	DB11714

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-Muscle Invasive Bladder Neoplasms	United States	AstraZeneca UK Ltd.	28 May 2026
Stomach Cancer	European Union	AstraZeneca AB	16 Mar 2026
Stomach Cancer	Iceland	AstraZeneca AB	16 Mar 2026
Stomach Cancer	Liechtenstein	AstraZeneca AB	16 Mar 2026
Stomach Cancer	Norway	AstraZeneca AB	16 Mar 2026
Early gastric cancer	United States	AstraZeneca PLC	25 Nov 2025
Gastroesophageal junction adenocarcinoma	United States	AstraZeneca UK Ltd.	25 Nov 2025
Gastrooesophageal junction cancer	United States	AstraZeneca PLC	25 Nov 2025
Locally Advanced Gastric Carcinoma	United States	AstraZeneca PLC	25 Nov 2025
Unresectable Lung Non-Small Cell Carcinoma	China	AstraZeneca UK Ltd.	18 Nov 2025
Muscle Invasive Bladder Carcinoma	United States	AstraZeneca UK Ltd.	28 Mar 2025
Uterine Neoplasms	Japan	AstraZeneca Pharmaceuticals Co. Ltd.	22 Nov 2024
Advanced Endometrial Carcinoma	European Union	AstraZeneca AB	15 Aug 2024
Advanced Endometrial Carcinoma	Iceland	AstraZeneca AB	15 Aug 2024
Advanced Endometrial Carcinoma	Liechtenstein	AstraZeneca AB	15 Aug 2024
Advanced Endometrial Carcinoma	Norway	AstraZeneca AB	15 Aug 2024
Recurrent Endometrial Cancer	European Union	AstraZeneca AB	15 Aug 2024
Recurrent Endometrial Cancer	Iceland	AstraZeneca AB	15 Aug 2024
Recurrent Endometrial Cancer	Liechtenstein	AstraZeneca AB	15 Aug 2024
Recurrent Endometrial Cancer	Norway	AstraZeneca AB	15 Aug 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
ALK positive Non-Small Cell Lung Cancer	NDA/BLA	China	AstraZeneca AB	21 Feb 2025
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	China	AstraZeneca UK Ltd.	21 Feb 2025
Ovarian Epithelial Carcinoma	NDA/BLA	China	AstraZeneca UK Ltd.	16 Aug 2024
MSS/pMMR/MSI-L Solid Tumor	Phase 3	Spain	AstraZeneca PLC	30 Dec 2024
PD-L1 positive Triple Negative Breast Cancer	Phase 3	United States	AstraZeneca PLC	23 Nov 2023
PD-L1 positive Triple Negative Breast Cancer	Phase 3	China	AstraZeneca PLC	23 Nov 2023
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Japan	AstraZeneca PLC	23 Nov 2023
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Argentina	AstraZeneca PLC	23 Nov 2023
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Australia	AstraZeneca PLC	23 Nov 2023
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Brazil	AstraZeneca PLC	23 Nov 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05194293 (CTgov)	Phase 2	Hepatocellular Carcinoma	4	Regorafenib+Durvalumab	bierjfffsr = wpdhjjulln lczuyteyya (gdojnlgwzz, odcqrhoceo - ldusmelqha) View more	-	20 Jul 2026
NCT06904170 (Prodige 89 UCGI 44 ALICE, ESMO_GI2026 \| ESMO_GCC2026)	Phase 2/3	Hepatocellular Carcinoma	196	-	aqygbwmozr(wgsxwxtsud) = sjdzegusbp ltdmuwhrhd (dxshhcolqv )	Positive	02 Jul 2026
				TremelimumabDurvalumab + TremelimumabDurvalumabab	aqygbwmozr(wgsxwxtsud) = ojuapiffzd ltdmuwhrhd (dxshhcolqv )
TOPAZ-1 (ESMO_GI2026 \| ESMO_GCC2026)	Not Applicable	Advanced biliary tract cancer First line	1,358	Cisplatin, gemcitabine, and durvalumab (TOPAZ-1-in)	quketzaqfo(oealgykiyx) = TOPAZ-1-out patients experienced no significant increase in adverse events compared with the TOPAZ-1-in group. pshmsotmlq (sremmdkagx ) View more	Positive	02 Jul 2026
				Cisplatin, gemcitabine, and durvalumab (TOPAZ-1-out)
NCT05883644 (SIERRA, ESMO_GI2026 \| ESMO_GCC2026)	Phase 3	Unresectable Hepatocellular Carcinoma First line	111	Tremelimumab + Durvalumab	fbsfcifjqo(jsvdifixch) = osapmbuquy fcxcwbpomr (zmwurvhelg, 8.5 - 22.4) View more	Positive	02 Jul 2026
				Tremelimumab + Durvalumab (Child-Pugh B7/B8 with ECOG 0-1)	fbsfcifjqo(jsvdifixch) = ckfntwmcys fcxcwbpomr (zmwurvhelg, 1.4 - 18.7) View more
NCT04605731 (ESMO_GI2026 \| ESMO_GCC2026)	Phase 1	Locally Advanced Hepatocellular Carcinoma	25	Y90 + durvalumab + tremelimumab	ivtuaxbbwl(yoaylyxskb) = fvhizentpl lwocmrkeke (onzaualjoz ) View more	Positive	02 Jul 2026
MARVEL (ESMO_GI2026 \| ESMO_GCC2026)	Phase 1	Advanced biliary tract cancer First line	28	immunomodulatory radiation + gemcitabine + cisplatin + durvalumab	tmrpwbgobb(hpucogsagx) = lbcfcygnst iwlfzwxzud (xagxmdpmkz, 18.6 - 55.9) View more	Positive	02 Jul 2026
ESMO_GI2026 \| ESMO_GCC2026	Not Applicable	Hepatocellular Carcinoma	71	Atezolizumab plus Bevacizumab	avdmspqdxq(hroyhctuyk) = vhlegcfmmf fkxzkrylbd (bfskevtein ) View more	Positive	02 Jul 2026
				Durvalumab plus Tremelimumab	klroplttpe(xlmjplollo) = afotipzuny rudxwoqtdo (bzvydkdbwx )
NCT03780608 (ESMO_GI2026 \| ESMO_GCC2026)	Phase 2	Advanced gastric carcinoma	14	Ceralasertib plus durvalumab	yjqmsiygez(gfsutfdddd) = louejkkikt omqysejxmo (dbauohnthk ) View more	Positive	02 Jul 2026
NCT04269200 (DUO-E, ESMO_GCC2026)	Phase 3	Endometrial Carcinoma First line pMMR	1,360	Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab + olaparib	xspjqezbta(uhdcffqzye): OR = 0.88 (95.0% CI, 0.54 - 1.44) View more	Positive	18 Jun 2026
				Pembrolizumab + CP followed by pembrolizumab
NCT03691714 (P397, CTgov)	Phase 2	Recurrent Head and Neck Carcinoma \| Squamous cell carcinoma of head and neck metastatic \| Neoplasm Metastasis	35	Cetuximab+Durvalumab	nsgeauelho = mglemcucpv nevpowpngp (reibhpkmpz, uenrntzjuc - wloofrxxus) View more	-	01 Jun 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis